Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alisartan/sacubitril - Shenzhen Salubris Pharmaceuticals

Next Previous
Drug Profile

Alisartan/sacubitril - Shenzhen Salubris Pharmaceuticals

Alternative Names: Alisartan calcium/sacubitril - Shenzhen Salubris Pharmaceuticals; Allisartan calcium/sacubitril - Shenzhen Salubris Pharmaceuticals; S-086; Sacubitril/alisartan calcium - Shenzhen Salubris Pharmaceuticals; Sacubitril/allisartan calcium - Shenzhen Salubris Pharmaceuticals; SAL-086; Xinchaotuo

Latest Information Update: 20 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Salubris Pharmaceuticals
  • Class Antihypertensives; Biphenyl compounds; Cardiovascular therapies; Esters; Heart failure therapies; Pentanoic acids; Small molecules
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Hypertension
  • Phase III Chronic heart failure; Essential hypertension

Most Recent Events

  • 18 Mar 2026 Shenzhen Salubris Pharmaceuticals expects to submit the NDA of S 086 to the NMPA for the treatment of chronic heart failure with reduced ejection fraction (HFrEF) in 2026
  • 24 Nov 2025 Shenzhen Salubris Pharmaceuticals completes a phase III trial in Essential hypertension (Combination therapy) in China (PO) (NCT07704697)
  • 31 May 2025 Preregistration for Hypertension in China (PO) prior to May 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top